Maine Medical Center and MHCCN
CANCER REGISTRY REPORT
| Page 2022
2 | Page TABLE OF CONTENTS 3 About the Cancer Registry 4 National Accreditation Programs 5 Achievements 8 MMC Cancer Registry Data Report 14 MaineHealth Cancer Care Network Registry Data Report 22 Acknowledgements
Senior Director
Evie Taylor RN, BSN, MHA
Director of Quality
Lauren Couture MS
Registry Supervisor
Cynthia Hayward CTR
Quality Coordinator
Shannon Lessard CTR
Certified Tumor Registrars
Autumn Bridges
Samantha Brooks (Mid Coast)
Tiffany Ervin (Mid Coast)
Brenda Gammon
Pamela Gantt
Melanie Ouellet
Cindy Poole (SMHC)
Laura Reinbach
Arthur West
Christina Wolfgang
About the Cancer Registry
Cynthia Hayward CTR
Please note the 2022 Cancer Registry Annual Report is completed in 2022, but reflects data on cases diagnosed in 2021.
What is a Cancer Registry?
A Cancer Registry is an information system designed for the collection, storage, and management of data on persons diagnosed with cancer. Registries play a critical role in cancer surveillance, which tells us where we are in the efforts to reduce cancer burden. Surveillance data may also serve as a foundation for cancer research and is used to plan and evaluate cancer prevention and control interventions.
By Maine state law, all cancer registries must submit data to the state’s cancer registry. Additionally, hospital cancer programs accredited by the Commission on Cancer (CoC) submit their data to the National Cancer Data Base (NCDB) annually.
MMC Cancer Registry Team
A cancer registrar (CTR) is a data collection specialist who paints a holistic picture of a patient’s medical history by looking at the diagnosis, treatment, and disease status for each patient. The case abstraction process is a vital component for supporting providers, unifying cancer treatment details from various systems, and providing summarized statistics for reportable patient trends. Together, the MMC Registry team maintains a data system which is designed for the collection, management, and analysis of data on individuals diagnosed with cancer.
Registry Coordinator
Heidi MacIver
Data Analyst
Emma Kurchin
3 | Page
National Accreditation Programs
Maine Medical Center (MMC) is accredited, certified, and/or recognized by several professional healthcare and third-party organizations.
Commission on Cancer (CoC)
In 2019, MMC was reaccredited by the Commission on Cancer (CoC), a quality program of the American College of Surgeons (ACOS). The CoC recognizes cancer programs for their commitment to providing high-quality, comprehensive, and integrative patient-centered care. This accreditation recognizes programs that meet the CoC standards and are dedicated to prevention, research, and education, and providing the best in patient-centered care.
National Accreditation Program for Breast Centers (NAPBC)
MMC received a three-year/full accreditation designation in 2019 by the National Accreditation Program for Breast Centers, a program administered by the American College of Surgeons. Accreditation is granted to centers that have voluntarily committed to provide the highest level of quality breast care and to undergo a rigorous evaluation process and review of their performance.
National Accreditation Program for Rectal Cancer (NAPRC)
In 2022, Maine Medical Center earned a three-year initial accreditation from the NAPRC. It is one of two programs in New England and only 45 in the nation to achieve this recognition.
American College of Radiology (ACR)
MMC Radiation Oncology became ACR-accredited in 2006. ACR Accreditation is a self-assessment and peer review process focused on diagnostic image quality, staff qualification, policies, protocols, equipment, and therapeutic treatment. It allows facilities to set and surpass industry-accepted quality standards for patient care and includes recommendations for improvement.
4 | Page
Quality Oncology Practice Initiative
The MaineHealth Cancer Care Network (MHCCN) is pursuing Quality Oncology Practice Initiative (QOPI) certification for eight outpatient hematology-oncology practices in the network. In 2023, the MHCCN will be submitting for our first site survey, and once approved, this will make us the first health system in the nation to achieve this level of certification.
QOPI is a quality program through the American Society of Clinical Oncology (ASCO), designed for outpatient oncology practices to foster a culture of self-examination and improvement. Participating practices can report on evidence-based quality measures and receive individual performance scores by practice, site, and provider, as well as benchmarked scores aggregated from all participating practices. Practices use this performance data to identify, develop, and implement quality improvement initiatives, leading to better care and better outcomes for their patients. Practices wanting to apply for QOPI certification must first complete the QOPI Certification Program Track and achieve a 55% or greater compliance. The MHCCN passed its first round of automated abstracting using CancerLinQ with an aggregate score of 67.6% - exceeding the required goal of 55%. In CY22, the MHCCN achieved a 73.6% aggregate score for the 20 QCP measures, demonstrating strong progress as we proceed with the certification process.
5 | Page Achievements
67.61% 73.6% 64.00% 65.00% 66.00% 67.00% 68.00% 69.00% 70.00% 71.00% 72.00% 73.00% 74.00% 75.00% Initial Submission - Jan. 2022 CY22 QOPI CQP Aggregate Score Date MHCCN QOPI QCP Aggregate Score
Nationally Accredited Programs in the Network
In 2022, MaineGeneral was surveyed for reaccreditation by the American Society of Clinical Oncology for the QOPI certification. In 2024, they will undergo CoC site survey for accreditation renewal.
In 2022, Mid Coast Hospital was reaccredited by the Commission on Cancer (CoC), a quality program of the American College of Surgeons.
In 2022, Southern Maine Health Care was reaccredited by the Commission on Cancer (CoC), a quality program of the American College of Surgeons. In 2023, they will undergo NAPBC site survey for accreditation renewal.
In 2022, St. Mary’s Regional Medical Center was reaccredited by the Commission on Cancer (CoC), a quality program of the American College of Surgeons. St. Mary’s was also reaccredited by the National Accreditation Program for Breast Centers, a program administered by the American College of Surgeons.
Survivorship and Care Plans
The MHCCN Survivorship Program, under the leadership of Amy Litterini, PhD, has expanded its scope to include new programming and communication touchpoints for our patients.
Among program enhancements are a Surgical Oncology pre-habilitation pilot, helping patients to physically and mentally prepare for surgery before the actual procedure; our tobacco cessation and monitoring program, geared toward informing patients who use tobacco products post treatment about making healthy lifestyle choices; and a newly-launched digital Survivorship quarterly, Thrive, for adult survivors, caregivers, community partners, and clinicians across the network with content inclusive of every aspect of the cancer experience.
Sanyal Named Senior Medical Director for the MHCCN
In May 2022, Amit Sanyal, MD, MHCDS, was named Senior Medical Director, MHMG-Medical Oncology and Director, Division of Medical Oncology at MMC. He joins us from the Sister of St. Mary’s Health System, where he served most recently as Regional Director of Medical Oncology.
Dr. Sanyal graduated from one of the two most prestigious apex medical schools in IndiaPostgraduate Institute of Medical Education & Research in Chandigarh. From there he pursued internal medicine training and his hematology/medical oncology fellowship both at the University of Wisconsin. He spent the next 16 years in professional practice in Madison, assuming the role of Regional Director in 2020. Dr. Sanyal is the consummate clinician, a thoughtful leader, and has a keen grasp of contemporary cancer care in a health system such as ours. He especially values our academic pursuits – both undergraduate and graduate hematology and oncology training and clinical research that we have established as foundational for our community and rural cancer care network.
6 | Page
NCI Community Oncology Research Program
In August 2019, MaineHealth was one of two new organizations to join the prestigious NationalCancerInstitute(NCI) CommunityOncologyResearchProgram(NCORP). The MaineHealth NCORP is a six-year, $5.1M project (PI: S. Remick, 1UG1 CA239771).
Highlights over the first three years of our project period include the following:
Successful recruitment of >60% patients enrolled on clinical trials living in rural settings;
Fourth-leading accruer in US (see right) in NCI’s high-priority Cancer MoonshotSM Biobank (CMB) study, a longitudinal study that collects multiple tissue and blood samples, along with medical information, from cancer patients. As of 02/13/2023, we have enrolled 183 participants, approximately 80% of whom live in rural locations;
Two supplemental awards totaling an additional $412,000, supporting an MHCCN cancer workforce Covid-19 seroprevalence study and community engagement activities as part of CMB;
Four of our investigators with standing representation on NCI Steering Committees and Task Forces:
o Dr. Leslie Bradford, Gynecology Oncology
o Dr. Christine Lu-Emerson, Neuro-Oncology
o Dr. Sharon Siegel, Radiology and
o Dr. Vatche Tchekmedyian, Head & Neck Oncology.
Other Quality Initiatives
Quality programs and initiatives are a leading area of focus for the MHCCN. Under the leadership of Evie Taylor, RN, BSN, MHA, Senior Director of Oncology Outpatient Services, and Lauren Couture, BS, MS, Director of Quality, our overall approach to quality has evolved over the past year with the introduction of more robust and sophisticated quality reporting and analytical tools.
Previously our quality work existed in the care-delivery space, heavily dependent on static data reporting and patient outcomes. We have shifted the paradigm by adding data scientists to the team: we are now able to monitor real-time clinical performance as well as mine historical clinic and operational data through an integrated data warehouse. Lauren’s team has developed an operational dashboard that updates daily and daily and highlights key performance indicators. These data points help us better understand how to improve our care-delivery workflows and models more efficiently
7 | Page
MMC Cancer Registry Data Report
Figure 1.
MMC Five-year Analytic Cancer Case Volume
Over the years 2017 through 2021, the MMC cancer registry accessioned a growing number of analytic cancer cases. MMC, as part of the MaineHealth Cancer Care Network, treats the majority of new cancer cases in northern New England.
NOTE on 2020 data: With the coronavirus pandemic, there was a sharp decrease in the number of newly diagnosed cancer cases at MMC.
2021 MMC Cancer Case Incidence
There were 4,428 accessioned cases at MMC in 2021; 3,833 of these cases were analytic. Analytic cases reflect patients who were diagnosed and/or received part or all their first course of treatment at MMC.
8 | Page
Table 1.
New Cases Case Count % Cases Analytic 3,833 85% Non-Analytic 595 15% 3,128 3,209 3,615 3,456 3,833 0 500 1,000 1,500 2,000 2,500 3,000 3,500 4,000 4,500 2017 2018 2019 2020 2021
COVID-19
Pandemic
2021 MMC Top Ten Sites of Analytic Cancer Cases
The 10 cancers with the largest number of cases in 2021 were cancer of the breast, prostate, lung and bronchus, uterine corpus, melanoma of the skin, urinary bladder, thyroid, kidney and renal pelvis, colon, and pancreas.
2021 MMC Distribution of Analytic Cancer Cases by Body System
Percentages Based on 3,833 Total Volume
9 | Page
Table 2.
Primary Site Total Cases % Cases Breast 695 18.0% Prostate 497 13.0% Lung and Bronchus 396 10.0% Uterine Corpus 297 7.0% Melanoma of Skin 196 5.0% Urinary Bladder 137 4.0% Thyroid 129 4.0% Kidney and Renal Pelvis 125 3.5% Colon 121 3.5% Pancreas 115 3.0%
19% 15% 14% 9% 13% 8% 6% 2% 3% 2% 3% 1% 2% 3% Breast Digestive System
Genital System
Genital System
System
Male
Female
Respiratory
Urinary System Skin Endocrine Oral Cavity & Pharynx CNS Lymphoma
Myeloma Leukemia Other
Figure 2.
Table 3.
2021 MMC Leading Sites of New Cancer Cases by Sex
The rate of new cancer cases diagnosed and/or treated at MMC in 2021 was higher in females than males, with Breast Cancer topping the chart for females at 32% and Prostate Cancer topping the chart for males at 29% of diagnosed malignancies. Fifty-five percent of total new cancer cases were diagnosed in females and 45% of new cancer cases were diagnosed in males.
MALE FEMALE
Figure 3.
2021 MMC Distribution of Analytic Cancer Cases by Age at Diagnosis and Sex
10 | Page
Primary Site Total Cases % Cases Prostate 497 29% Lung and Bronchus 188 11% Urinary Bladder 108 6% Melanoma of Skin 102 6% Colon and Rectum 94 6% Oral Cavity and Pharynx 94 6% Kidney and Renal Pelvis 81 5% Pancreas 56 3% Non-Hodgkin Lymphoma 57 3% Leukemia 47 3% All Other Sites 383 22% Grand Total 1,707 100% Primary Site Total Cases % Cases Breast 690 32% Uterine Corpus 297 14% Lung and Bronchus 207 10% Thyroid 96 5% Colon and Rectum 91 4% Melanoma of Skin 89 4% Kidney and Renal Pelvis 44 2% Ovary 41 2% Non-Hodgkin Lymphoma 53 2% Leukemia 32 2% All Other Sites 486 23% Grand Total 2,126 100% 45% 55% 38 30 54 229 649 520 166 18 45 87 211 430 631 489 204 29 0 100 200 300 400 500 600 700 0 - 29 30 - 39 40 - 49 50 - 59 60 - 69 70 - 79 80 - 89 Other Age at Diagnosis by Sex Male Female
2021 MMC Cancer Cases by Age
Of all analytic accessioned cases in 2021, 60% of new cancer cases were diagnosed in people between the ages of 70 and 89. This chart shows that for most cancers, increasing age is the most significant risk factor.
2021 MMC Distribution of Analytic Cancer Cases by Race
2021 MMC Cancer Cases by Stage
Cancer staging is the process of determining how much cancer is in the body and where it is located. Staging describes the severity of an individual's cancer, based on the magnitude of the original (primary) tumor and the extent cancer has spread in the body. All staging completed at MMC is based on The American Joint Committee on Cancer (AJCC) standards.
11 | Page
Figure 4.
Figure 5.
2% 3% 7% 17% 34% 26% 10% 1% 0-29 30-39 40-49 50-59 60-69 70-79 80-89 90+
Table 4.
Race % Population White 97.29% Black 1.12% Unknown 0.50% Other 0.23% Vietnamese 0.18% Other Asian, including Asian/Oriental, NOS 0.16% American Indian, Alaska Native 0.16% Korean 0.08% Chinese 0.08% Asian Indian or Pakistani, NOS 0.05% Filipino 0.05% Asian Indian 0.05% Thai (effective with 1994 diagnoses) 0.03% Kampuchean (including Khmer and Cambodian) 0.03% Grand Total 100.00% 35% 15% 12% 14% 11% 13% Stg I Stg II Stg III Stg IV N/A UNK
2021 MMC Cancer Cases by Anatomic Site and Stage
12 | Page Table 5.
Primary Site Total Cases % Cases Stage 0 Stage I Stage II Stage III Stage IV N/A UNKNOWN ORAL CAVITY AND PHARYNX 139 3.6% 6 37 30 17 35 5 9 Lip 5 1.0% 0 2 1 0 1 1 0 Tongue 46 1.2% 3 15 9 5 9 2 3 Salivary Glands 15 0.4% 0 3 4 4 3 1 0 Floor of Mouth 12 0.3% 2 0 2 1 6 0 1 Gum and Other Mouth 17 0.4% 1 2 4 0 8 0 2 Nasopharynx 5 0.1% 0 0 0 2 2 1 0 Tonsil 27 0.7% 0 13 8 3 1 0 2 Oropharynx 3 0.1% 0 1 1 0 0 0 1 Hypopharynx 8 0.2% 0 1 1 1 5 0 0 Other Oral Cavity a Pharynx 1 0.0% 0 0 0 1 0 0 0 DIGESTIVE SYSTEM 534 13.9% 5 129 86 128 121 21 44 Esophagus 67 1.7% 1 7 6 18 22 1 12 Stomach 42 1.1% 0 4 6 10 18 2 2 Small Intestine 17 0.4% 0 4 4 5 2 2 0 Colon excluding Rectum 121 3.2% 1 27 27 31 19 1 15 Rectum and Rectosigmoid 64 1.7% 2 20 8 22 7 1 4 Anus, Anal Canal, and Anorectum 25 0.7% 0 4 6 10 2 1 2 Liver and Intrahepatic Bile Duct 45 1.2% 0 16 6 10 10 2 1 Gallbladder 7 0.2% 0 0 3 1 0 1 2 Other Biliary 18 0.5% 0 6 0 6 1 1 4 Pancreas 115 3.0% 1 41 20 10 39 2 2 Retroperitoneum 4 0.1% 0 0 0 2 0 2 0 Peritoneum, Omentum, and Mesentery 4 0.1% 0 0 0 3 1 0 0 Other Digestive Organs 5 0.1% 0 0 0 0 0 5 0 RESPIRATORY SYSTEM 432 11.3% 5 144 31 60 155 28 9 Nose, Nasal Cavity, and Middle Ear 9 0.2% 0 3 0 0 3 3 0 Larynx 26 0.7% 2 5 3 5 10 0 1 Lung and Bronchus 396 10.3% 3 136 28 55 142 24 8 Trachea, Mediastinum, and Other Respiratory Organs 1 0.0% 0 0 0 0 0 1 0 BONES & JOINTS 8 0.2% 0 2 2 0 1 3 0 SOFT TISSUE 15 0.4% 0 2 0 5 2 6 0 SKIN EXCLUDING BASAL AND SQUAMOUS 196 5.1% 55 65 18 21 14 4 19 Melanoma -- Skin 191 5.0% 55 64 17 21 14 1 19 Other Non-Epithelial Skin 5 0.1% 0 1 1 0 0 3 0
Table 5 (continued).
2021 MMC Cancer Cases by Anatomic Site and Stage
13 | Page
Primary Site Total Cases % Cases Stage 0 Stage I Stage II Stage III Stage IV N/A UNKNOWN BREAST 695 18.1% 126 424 78 32 19 2 14 FEMALE GENITAL SYSTEM 461 12.0% 0 258 21 69 26 19 68 Cervix Uteri 37 1.0% 0 18 5 7 3 0 4 Corpus and Uterus, NOS 297 7.7% 0 198 10 28 7 5 49 Ovary 41 1.1% 0 15 4 9 5 2 6 Vagina 4 0.1% 0 3 0 0 0 1 0 Vulva 33 0.9% 0 21 1 4 1 1 5 Other Female Genital Organs 49 1.3% 0 3 1 21 10 10 4 MALE GENITAL SYSTEM 514 13.4% 0 85 244 113 53 1 18 Prostate 497 13.0% 0 80 241 111 53 0 12 Testis 15 0.4% 0 4 3 2 0 1 5 Penis 2 0.1% 0 1 0 0 0 0 1 URINARY SYSTEM 273 7.1% 51 91 51 32 21 7 20 Urinary Bladder 137 360.0% 49 16 40 19 4 3 6 Kidney and Renal Pelvis 125 3.3% 1 73 10 10 15 4 12 Ureter 8 0.2% 1 2 1 1 2 0 1 Other Urinary Organs 3 0.1% 0 0 0 2 0 0 1 EYE AND ORBIT 1 0.0% 0 0 0 0 0 1 0 BRAIN AND OTHER NERVOUS SYSTEM 123 3.2% 0 0 0 0 0 123 0 Brain 64 1.7% 0 0 0 0 0 64 0 Cranial Nerves Other Nervous System 59 1.5% 0 0 0 0 0 59 0 ENDOCRINE SYSTEM 156 4.1% 0 102 20 2 5 24 3 Thyroid 129 3.4% 0 99 20 2 4 1 3 Other Endocrine including Thymus 27 0.7% 0 3 0 0 1 23 0 LYMPHOMA 127 3.3% 0 22 24 14 41 25 1 Hodgkin Lymphoma 17 0.4% 0 0 7 4 5 1 0 Non-Hodgkin Lymphoma 110 2.9% 0 22 17 10 36 24 1 MYELOMA 29 0.8% 0 2 3 0 0 23 1 LEUKEMIA 79 2.1% 0 2 0 0 0 76 1 Lymphocytic Leukemia 27 0.7% 0 2 0 0 0 24 1 Myeloid and Monocytic Leukemia 50 1.3% 0 0 0 0 0 50 0 Other Leukemia 2 0.1% 0 0 0 0 0 2 0 MESOTHELIOMA 6 0.2% 0 2 0 1 1 1 1 MISCELLANEOUS 45 1.1% 0 0 0 1 1 43 0 Grand Total 3833 100% 248 1367 608 495 495 412 208
MaineHealth Cancer Care Network Registry Data Report
14 | Page
MaineHealth Cancer Care Network Five-year Analytic Cancer Case Volume
Over the years 2017 through 2021, the cancer registries of the MHCCN accessioned a growing number of analytic cancer cases. The MHCCN treats the majority of new cancer cases in northern New England.
NOTE on 2020 data: With the coronavirus pandemic, there was a sharp decrease in the number of newly diagnosed cancer cases in the MHCCN..
2021 MHCCN Cancer Case Incidence
There were 8,113 accessioned cases at the MHCCN in 2021; 7,057 of these cases were analytic. Analytic cases reflect patients who were diagnosed and/or received part or all their first course of treatment at the MHCCN.
15 | Page
Figure 6.
Table 6.
New Cases Case Count % Cases Analytic 7,057 87% Non-Analytic 1,056 13% COVID-19 Pandemic 6,198 6,438 7,019 6,586 7,057 5,600 5,800 6,000 6,200 6,400 6,600 6,800 7,000 7,200 2017 2018 2019 2020 2021
Page
Table 7.
2021 MHCCN Cancer Case Incidence Summary by Facility
Figure 8.
MaineGeneral Medical Center Facility 2021 ANALYTIC 2021 TOTAL VOLUME Maine Medical Center 3,833 4,428 Southern Maine Health Care 500 550 Maine General Medical Center 1,192 1,342 Mid Coast Hospital 410 448 St. Mary’s Regional Medical Center 154 203 Pen Bay Medical Center 323 355 Waldo County General Hospital 147 170 Western Maine Health Care 128 147 Lincoln Health 62 75 Memorial Hospital 153 231 Franklin Community Health 155 164 TOTAL 7,057 8,113 DE-DUPLICATED 6,411 7,332 Primary Site Total Cases Lung and Bronchus 246 Breast 198 Prostate 128 Melanoma of Skin 72 Urinary Bladder 61 Hematopoietic 60 Colon 44 Pancreas 36 Rectum 31 Esophagus 29
2021 MHCCN Top Ten Analytic Sites and Leading Sites of New Cancer Cases by Sex
17 | Page
Primary Site Total Cases Breast 99 Prostate 77 Lung & Bronchus 64 Melanoma of Skin 54 Colon 35 Urinary Bladder 24 Corpus Uteri 20 Kidney 20 Esophagus 14 Rectum 12
Coast Hospital Primary Site Total Cases Breast 105 Prostate 60 Urinary Bladder 46 Lung and Bronchus 29 Colon 21 Corpus Uteri 16 Melanoma of Skin 14 Hematopoietic 13 Esophagus 13 Lymph Nodes 12
Southern Maine Health Care
Mid
Pen Bay Medical Center
Franklin Memorial Hospital
18 | Page
Primary Site Total Cases Prostate 54 Breast 43 Melanoma of Skin 34 Urinary Bladder 33 Lung and Bronchus 25 Hematopoietic 21 Colon 19 Corpus Uteri 11 Esophagus 8 Pancreas 8
Primary Site Total Cases Prostate 43 Breast 31 Melanoma of Skin 13 Bladder 11 Colon 10 Lung and Bronchus 9 Rectum 8 Esophagus 6 Hematopoietic 4 Other 3
Memorial Hospital (NH)
Waldo County General Hospital
19 | Page
Primary Site Total Cases Breast 27 Prostate 26 Lung and Bronchus 18 Hematopoietic 13 Corpus Uteri 8 Urinary Bladder 8 Melanoma of Skin 7 Pancreas 7 Colon 6 Liver and Bile Duct 6
Primary Site Total Cases Breast 49 Hematopoietic 14 Lung and Bronchus 14 Colon 8 Lymph Nodes 7 Unknown Primary Site 6 Urinary Bladder 6 Corpus Uteri 6 Rectum 6 Prostate 4
St. Mary’s Regional Medical Center
Western Maine Health Care
20 | Page
Primary Site Total Cases Breast 35 Prostate Gland 32 Lung and Bronchus 30 Colon 11 Hematopoietic 10 Urinary Bladder 9 Kidney 5 Melanoma of Skin 4 Rectum 4 Other 2
Primary Site Total Cases Breast 25 Colon 13 Lung and Bronchus 12 Hematopoietic 10 Corpus Uteri 8 Lymph Nodes 8 Urinary Bladder 6 Meninges 5 Prostate Gland 5 Melanoma of Skin 4
Lincoln County Health Care
21 | Page
Primary Site Total Cases Breast 17 Melanoma of Skin 7 Lung and Bronchus 6 Hematopoietic 4 Lymph Nodes 3 Prostate Gland 3 Corpus Uteri 3 Colon 3 Stomach 2 Tonsil 2
Acknowledgements
The MHCCN leadership would like to extend our sincere gratitude to the entire MaineHealth Cancer Registry team. Without your dedication, we would not be where we are today. We would like to recognize the following individuals for their contributions to the MMC, SMHC, and Mid Coast Cancer Registries:
Thank you to all our CTRs, for your dedication and hard work throughout the year. In 2022, you all have completed a total of 4,475 case abstractions, analytical and nonanalytical, which is a 17.5 % increase in case volume over the last five years.
Thank you to Cynthia Hayward, Cindy Poole, and Tiffany Ervin for your invaluable assistance in supporting Mid Coast Hospital during our recent transition period. Your effort to help maintain our compliance for the CoC Survey and for unifying reporting policies between MMC, SMHC, and Mid Coast does not go unnoticed.
A special thank you to Meaghan Bumpus, Shannon Lessard, Cindy Poole, and Tiffany Ervin, for their exponential work in meeting deadlines for CoC, NAPBC, and NAPRC accreditations and site surveys for MMC, SMHC, and MCH. We could not have supplied all the necessary registry metrics and reporting without your support.
A special thank you to Heidi MacIver for her level of dedication in casefinding for the MMC Cancer Registry. Casefinding is an important part of our work as diagnosis is the first step in the patient’s cancer journey.
And one more, to Emma Kurchin and Heidi MacIver, for their hard work in maintaining patient follow-up percentage rate as required by the CoC.
Evie Taylor RN, BSN, MHA Senior Director of Outpatient CareMaineHealth Cancer Care Network and Maine Medical Center
Lauren Couture MS Director
ofQuality, Information, Research and Outcomes
MaineHealth Cancer Care Network and Maine Medical Center
Cindy Hayward CTR Cancer Registry SupervisorMaineHealth Cancer Care Network and Maine Medical Center
22 | Page
